AKBA Q2 2019 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$366M

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$101M+106.6% YoY

Gross Profit

$63M62.6% margin

Operating Income

-$60M-59.0% margin

Net Income

-$58M-57.7% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

+38.7%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$40M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$824M

Total Liabilities

$304M

Stockholders' Equity

$519M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$101M	$49M	+106.6%
Gross Profit	$63M	-$23M	+373.0%
Operating Income	-$60M	-$36M	-66.9%
Net Income	-$58M	-$34M	-70.7%

Revenue Segments

License Collaboration And Other Revenue

$10M100%